Sclerotherapy Verus Propranolol After a Variceal Bleed by Van Stiegmann, Gregory
178 HPB INTERNATIONAL
operation11. Until surgeons are more alert to a preoperative or peroperative
diagnosis and until the limits of radical surgery are defined the further treatment of
gallbladder carcinoma invading perimuscular connective tissue but not serosa must
remain an open question.
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SCLEROTHERAPY VERUS PROPRANOLOL AFTER A
VARICEAL BLEED
ABSTRACT
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A prospective randomized study was conducted to compare the efficacy of long-term
endoscopic sclerotherapy versus propranolol in Child class B and C patients with
variceal bleeds within the 30 days before the study. Forty-five and 46 patients were
randomized to receive sclerotherapy and propranoloi, respectively, after preentry
stratification for Child scores. Sclero-therapy was administered with 1% polidocanol
at 10-day intervals until obliteration of varices was achieved. Propranoloi was
administered to achieve a reduction in resting pulse rate of 25%. Rebleeding
occurred in 19 patients undergoing sclerotherapy and in 31 receiving propranolol (p
< 0.05). The number of episodes of rebleeding was higher (p < 0.05) in the
propranolol group (n 64) than in the sclerotherapy group (n 35). The mean
bleeding risk factor, number of hospitalizations for rebleeding and blood transfusion
requirement were also significantly higher in the propranolol-treated patients. The
median bleed-free period was more than 36 mo in the sclero-therapy group and 2.5
mo in the propranolol group (p < 0.01). The median survival time was significantly
longer in the sclerotherapy group (> 36 mo) than in the propranolol group (> 24
mo). We conclude that in decompensated cirrhotic patients, long-term endoscopic
sclerotherapy is superior to propranolol in preventing rebleeding and improving
survival. (Hepatology, 1992; 16: 89-94).
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Dasarathy and colleagues have contributed the sixth published trial comparing the
beta adrenergic antagonist propranolol with serial endoscopic sclerotherapy for
prevention of recurrent bleeding from esophageal varices1. In contrast to some of
the previous studies, only Child-Pugh class B and C patients were entered. In
further contrast to all but one of the previous trials, a significant reduction in both
the incidence of recurrent bleeding from esophageal varices and in mortality was
observed in patients who had endoscopic treatment.
Table 1 summarizes information from the current trial and the five previously
published studies which compared endoscopic sclerotherapy with propranolol2-6.
Alexandrino et al. found a significant reduction in the incidence of recurrent
hemorhage from esophageal varices in sclerotherapy treated patients as well as a
trend toward improved survival. The latter was also observed by Westaby et al. and
Flieg et al. On the other hand, Dollet et al. demonstrated a trend toward less
rebleeding in patients treated with propranolol but had identical survival in each
treatment arm while Rossi et al. found no differences at all.
Can meaningful conclusions be drawn from six trials with such disparate results?
The wide variation in outcomes between these trials suggests several explanations:
patients in different trials were dissimiliar; endoscopic sclerotherapy was per-
formed more effectively in some trials; or the titration of propranolol and/or
compliance with taking the drug was better in some trials.
The latter seems least likely since all of the trials treated patients with proprano-
1ol to reduce resting pulse rates from 20 to 25% and compliance with taking the
drug was good. On the other hand, entry criteria, sclerotherapy technique, and
sclerotherapy treatment intervals varied widely across these studies. The majority
of patients in the five previously published trials had alcohol induced cirrhosis in180 HPB INTERNATIONAL
Table 1 Results of six prospective randomized trials which compared serial sclerotherapy with propranolol
for prevention of recurrent bleeding from esophageal varices. S=sclerotherapy, P propranolol, %
Rebled proportion of patients who experienced one or more episodes of recurrent hemorrhage from
esophagael varices, % Child C total proportion of Child-Pugh class C patients in both arms of trial,
% EtOH proportion of alcoholic cirrhotics in both arms of trial (*p>0.05)
Author / Patients Therapy %Rebled %Survival %Child C %EtOH
Flieg 36 S 28% 91% 30% 82%
(4) 34 P 29% 85%
Alexandrino 31 S 33%* 69% 0 80%
(2) 34 P 75%* 54%
Westaby 56 S 45% 66% 0 55%
(6) 52 P 54% 55%
Rossi 26 S 50% 80% 38% 100%
(5) 27 P 47% 79%
Dollet 28 S 64% 51% 27% 94%
(3) 27 P 44% 53%
Dasarathy 45 S 42% * 78% * 34% 27%
(1) 46 P 67%* 59%*
contrast to the Desarathy trial in which 73% had non-alcoholic liver disease. Two
of the previous trials completely excluded Child-Pugh class C patients and selection
was so careful in one that 83 percent of those admitted with bleeding varices were
eliminated:. Entry criteria for the Desarathy study were less exclusive. Specifically,
patients were not excluded, as in other studies, if transfusions for the index bleed
exceeded a fixed number (e.g. 6 or 10) of units of blood and all patients were
required to have grade four (large) esophageal varices and endoscopic signs
indicating a high risk of recurrent hemorrhage. Patients were also required to be
hemodynamically stable for a period of only 24 hours prior to randomization.
Other trials varied the time interval from the index bleed to randomization:
intervals ranged up to greater than 15 days. Methods of sclerotherapy varied
considerably among the studies and included both intravariceal (five trials) and
paravariceal injections administered repetitively at intervals as short as two to four
days and as long as three weeks until varices were eradicated. Patients who did
experience recurrent bleeding (both treatment groups) were treated medically
(vasoconstrictor plus balloon tamponade if needed) in five of the trials (including
Desarathy et al.) and shunt surgery or emergency sclerotherapy (the latter held by
many to be the optimal treatment for acute bleeding) was employed if bleeding
persisted after removal of the tamponade device. Only one trial employed emerg-
ency sclerotherapy at the time of the endoscopic diagnosis of recurrent bleeding
from varices6.
Is endoscopic sclerotherapy a better treatment than propranolol, particularly for
patients with poorly compensated liver disease? Results from the three previous
trials which included Child class C patients are inconclusive. More than 75 percent
of the patients in these three studies were in Child-Pugh class B and C but none of
these trials resulted in significant differences in outcome variables in favor of one
treatment over the other. Two of the three examined the incidence of rebleeding
and/or survival rates between cohorts when stratified by Child-Pugh class and foundHPB INTERNATIONAL 181
no differences, although the numbers of individual patients in each subset were
small. These data, derived predominately from selected patients with alcoholic
cirrhosis, support the conclusion that sclerotherapy, as employed in these studies,
was neither better nor worse than propranolol in the groups studied.
What conclusions then can be drawn from the study of Desarathy et al. which
convincingly demonstrates what all therapeutic endoscopists instinctively know--
that swallowing an endoscope is better than swallowing a pill? It is generally agreed
that propranolol may not be as effective for prevention of recurrent hemorrhage
from esophageal varices in patients with advanced liver disease as it is in those with
better preserved hepatic function. Results from the five previous sclerotherapy
versus propranolol trials do not fully support this conclusion but the very design of
two of them (Child-Pugh class C patients excluded) and the relatively stringent
entry criteria for the remainder suggest that selection of patients to be treated with
propranolol is very important. The etiology of cirrhosis also seems to play a role in
the success of pharmacological therapy with propranolol. The patient with non-
alcoholic cirrhosis appears to be at a disadvantage when treated with propranolol,
particularly when compared to the patient with alcoholic cirrhosis who refrains
from alcohol use. The findings of Dasarathy et al. are valuable because the patient
who is best treated with propranolol as an alternative to endoscopic or operative
therapy has yet to be precisely defined. Until results of this trial are confirmed and
such definitions are well established, the use of propranolol should remain confined
to carefully selected patients or those entered into controlled trials.
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